A Case of Foveoschisis Associated with Ornithine Aminotransferase Deficiency and Gyrate Atrophy.

J Coll Physicians Surg Pak

Department of Ophthalmology, University of Health Sciences, Beyoglu Eye Traininig and Research Hospital, Bereketzade, Bereketzade Cami Sk. No: 2, 34421 Beyoğlu/İstanbul, Turkey.

Published: November 2021

Gyrate atrophy is a metabolic disorder characterised by typical progressive circular chorioretinal atrophy, myopia and early developmental cataract. The disease is caused by deficiency of ornithine aminotransferase (OAT) enzyme. Although OAT is expressed in most tissues of the body, but the main target of the disease appears to be the retina. A case is presented here of a 21-year woman, who came to our clinic with the complaint of decline in central vision for eight months. She had progressive poor night vision and was diagnosed with OAT deficiency five years ago. Her systemic history was unremarkable, except for femoral deep vein thrombosis (DVT) which occurred two years ago. Laboratory tests performed at that time had revealed elevated serum ornithine and low serum lysin levels. Optic coherence tomography (OCT) scans showed foveoschisis bilaterally. In summary, gyrate atrophy may present as macular involvement in the form of foveoschisis and may lead to impaired central vision. Key Words: Foveoschisis, Gyrate atrophy, Ornithine aminotransferase.

Download full-text PDF

Source
http://dx.doi.org/10.29271/jcpsp.2021.11.1354DOI Listing

Publication Analysis

Top Keywords

gyrate atrophy
16
ornithine aminotransferase
12
central vision
8
years ago
8
atrophy
5
case foveoschisis
4
foveoschisis associated
4
ornithine
4
associated ornithine
4
aminotransferase deficiency
4

Similar Publications

Novel Insights Into Gyrate Atrophy of the Choroid and Retina (GACR): A Cohort Study.

J Inherit Metab Dis

January 2025

Department of Pediatrics, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Gyrate atrophy of the choroid and retina (GACR, OMIM #258870) is a rare inherited metabolic disorder characterized by progressive chorioretinal degeneration and hyperornithinemia. Current therapeutic modalities potentially slow disease progression but are not successful in preventing blindness. To allow for trial development, increased knowledge of the clinical phenotype and current therapeutic outcomes is required.

View Article and Find Full Text PDF

Purpose: Description of retinal phenotype by structural and functional testing, ornithine plasma levels and mutational data of OAT gene in patients with Gyrate Atrophy (GA).

Methods: Ophthalmologic examination, fundus photography (CFP), autofluorescence (FAF), spectral-domain optical coherence tomography (SD-OCT), Goldmann perimetry (GP), full-field electroretinogram (ffERG) and chromatic perimetry (CP) testing were performed. Ornithine plasma levels were measured.

View Article and Find Full Text PDF

A mini-review on the international gyrate atrophy symposium 2023: More than meets the eye. Focus on outstanding research questions.

Mol Genet Metab

December 2024

Department of Pediatrics, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Gastroenterology, Endocrinology and Metabolism, Amsterdam, University of Amsterdam, Amsterdam, the Netherlands; Laboratory Genetic Metabolic Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Department of Ophthalmology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Department of Human Genetics, Section Ophthalmogenetics, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Department Endocrinology and Metabolism Amsterdam UMC, Department of Nutrition and Dietetics, Amsterdam University Medical Center, Amsterdam, the Netherlands; Emma Center for Personalized Medicine, Amsterdam UMC, Amsterdam, Netherlands.

View Article and Find Full Text PDF

Combined intraocular and intravenous gene delivery for therapy of gyrate atrophy of the choroid and retina.

Mol Ther

October 2024

Telethon Institute of Genetics and Medicine (TIGEM), 80078 Pozzuoli, Italy; Gene Therapy Joint Lab, Department of Advanced Biomedical Sciences and Department of Translational Medicine, "Federico II" University, 80131 Naples, Italy; Scuola Superiore Meridionale (SSM, School of Advanced Studies), Genomics and Experimental Medicine Program, "Federico II" University, 80131 Naples, Italy. Electronic address:

Gyrate atrophy of the choroid and retina (GACR) is due to ornithine aminotransferase (OAT) deficiency, which causes hyperornithinemia, leading to retinal pigment epithelium, followed by choroidal and retinal degeneration. Adeno-associated virus serotype 8 (AAV8) vector-mediated OAT (AAV8-OAT) liver gene transfer reduces ornithinemia in the Oat mouse model of GACR and improves retinal function and structure. Since OAT is expressed in various tissues including the retina, we investigated the efficacy of restoration of OAT expression in either retina or liver or both tissues on the retinal phenotype of Oat mice.

View Article and Find Full Text PDF

Objective: To profile a cohort of gyrate atrophy patients classified by widefield retinal imaging and correlate the structural, biochemical, and functional characteristics.

Design: Retrospective observational cohort study.

Participants: Sixty-five patients (129 eyes) with gyrate atrophy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!